Abstract

Adecoagro SA will report quarterly results on May 11, 2026 after market close, with the market looking for a material rebound in earnings and a strong year-over-year increase in revenue.

Market Forecast

Consensus and company-tracked projections for the current quarter indicate revenue of 436.18 million US dollars, up 32.02% year over year, EBIT of 82.42 million US dollars, up 1,781.69% year over year, and EPS of 0.237, up 363.33% year over year; formal guidance for gross profit margin and net margin has not been provided in the dataset. The main business is expected to sustain momentum as price realization and unit productivity normalize against last year’s depressed base, positioning overall profitability to recover in tandem with the EBIT and EPS outlook. The company’s most promising near-term growth vector is the agricultural production and biological assets operation, which generated about 55.03 million US dollars last quarter; year-over-year growth by segment was not disclosed, but sequential volume and pricing conditions point to a firmer contribution in the current quarter.

Last Quarter Review

Adecoagro SA posted revenue of 415.94 million US dollars, a gross profit margin of 18.68%, GAAP net loss attributable to the parent company of 14.85 million US dollars, a net margin of -3.57%, and adjusted EPS of -0.15, with revenue up 11.15% year over year and adjusted EPS down 132.61% year over year; the sequential change in GAAP net profit was -327.87%. The company outperformed on top line versus the prior estimate, beating revenue by 11.83%, while EBIT came in at 36.13 million US dollars (down 24.97% year over year) and exceeded the tracked estimate by 20.29 million US dollars. Main-business composition remained concentrated in manufactured products and services at 86.77% of sales (approximately 360.91 million US dollars), with agricultural production and biological assets at 13.23% (approximately 55.03 million US dollars); segment-level year-over-year rates were not disclosed in the dataset.

Current Quarter Outlook

Main Business: Manufactured Products and Services

Manufactured products and services, which represented 86.77% of last quarter’s revenue, remains the principal earnings engine entering this print. The forecast combination of 32.02% revenue growth year over year, 1,781.69% EBIT growth year over year, and a 363.33% jump in EPS implies a powerful rebound in operating leverage against last year’s trough, with mix and pricing likely the central drivers. While the dataset does not include explicit gross or net margin guidance, the magnitude of the EBIT and EPS recovery suggests margin normalization toward historical ranges as fixed-cost absorption improves and cost pressure abates relative to last year’s comparable period.

The operational setup also aligns with a better sequential trajectory versus the prior quarter’s negative net margin and difficult quarter-on-quarter net income swing. Management’s execution on overhead control, unit productivity, and commercial hedging should translate into a cleaner drop-through from revenue to EBIT, which is consistent with the 82.42 million US dollars EBIT estimate. In monitoring this line of business, investors should track realized pricing, throughput/efficiency metrics, and any update on inventory carryover that could affect recognition timing and the gross-to-operating margin bridge.

Most Promising Business: Agricultural Production and Biological Assets

The agricultural production and biological assets segment contributed approximately 55.03 million US dollars last quarter and is positioned to deliver the highest incremental impact on earnings variability near term. Although the dataset does not provide a segment-specific year-over-year growth rate, the consolidated forecast implies that this unit should benefit from enhanced volume execution and more favorable valuation marks versus last year’s difficult comparison. The effect of biological-asset accounting often amplifies quarter-to-quarter earnings swings; as volumes normalize and pricing signals stabilize, the distribution of outcomes narrows, providing a clearer path to EBIT scaling.

From a P&L perspective, this segment’s influence shows up in both gross margin and below-gross-margin lines when fair-value movements are recognized. A better operating run-rate and timely commercialization decisions can help align biological-asset remeasurement effects with cash conversion, smoothing volatility and improving visibility into net margin. Against this backdrop, the expected rebound in consolidated EPS and EBIT this quarter suggests a smaller drag from non-cash valuation effects and stronger realized contribution from marketed output.

What Will Drive the Stock This Quarter

The quarter’s stock reaction will hinge on the credibility and quality of the earnings beat or miss relative to the 436.18 million US dollars revenue estimate and the pace of margin normalization implied by the 82.42 million US dollars EBIT outlook. Investors will focus on whether gross margin can visibly improve from last quarter’s 18.68% and whether the net margin, which was -3.57% last quarter, can inflect into positive territory or at least narrow sharply negative, consistent with the large EPS and EBIT rebounds implied by forecasts. Any commentary on cost discipline, hedging results, inventory monetization, and working-capital release will be crucial for assessing the sustainability of cash generation beyond the current quarter.

Another near-term swing factor is the cadence of sequential improvement compared with the previous quarter’s weak net result, which fell sharply on a quarter-on-quarter basis. Evidence that sequential profitability is tracking toward a stronger second half would reinforce the sturdiness of the 363.33% year-over-year EPS rebound. Finally, the market will evaluate how revenue mix evolves within the main business and agricultural production units, as changes in mix can meaningfully shift consolidated margins and cash conversion even if headline revenue lands near consensus.

Analyst Opinions

Bullish opinions outweigh bearish views in the year-to-date window through May 4, 2026, with a ratio of 2:1 when considering buy/overweight versus sell calls. UBS upgraded Adecoagro SA to Buy and lifted the price target to 16.20 US dollars, highlighting improved earnings visibility and a more favorable balance of risk and reward into this reporting cycle. Recent aggregated assessments also show an average rating skewed to Overweight with an average price target around the mid-teens, reinforcing the constructive stance heading into the print.

The bullish cohort emphasizes three elements behind their positive view. First, consensus modeling for the quarter implies a strong rebound in profitability, with EBIT estimated at 82.42 million US dollars, up 1,781.69% year over year, and EPS forecast at 0.237, up 363.33% year over year; this suggests that the trough conditions that pressured last year’s comparables have eased, allowing the business to translate higher sales into material operating leverage. Second, despite the lack of formal gross and net margin guidance, the scale of the projected EPS and EBIT recovery supports the idea that margin normalization is underway, which underpins the upgraded ratings and higher price targets. Third, the revenue estimate of 436.18 million US dollars implies 32.02% year-over-year growth, and bullish analysts see upside risk if unit productivity and commercialization timing outperform internal assumptions, particularly in the core manufactured products and services line.

UBS’s upgrade to Buy, paired with the overweight-leaning aggregate stance, frames expectations around not just a headline beat potential but also a cleaner quality of earnings. For investors, the emphasis from the bullish side is on the durability of the improvement: they will look for evidence that cost controls, price realization, and volume cadence can sustain margins beyond a single quarter. On balance, the majority view is that Adecoagro SA is transitioning into a period of improved profitability relative to last year’s baseline, with near-term catalysts centered on meeting or exceeding the ambitious EBIT and EPS trajectory embedded in current estimates.